What Is Melan-A and Its Role in Melanoma?

Melan-A, also known as MART-1 (Melanoma Antigen Recognized by T cells-1), is a protein produced by melanocytes that serves double duty in medicine: it helps pathologists identify melanoma under the microscope, and it gives the immune system a target to attack melanoma cells. The protein was first isolated in the mid-1990s through studies of tumor-infiltrating immune cells that could recognize and kill melanoma, and its significance has only grown since then. Understanding Melan-A matters because it sits at the intersection of diagnosis, prognosis, and treatment for one of the most aggressive skin cancers.

What Melan-A Actually Does in Normal Cells

In healthy skin, melanocytes produce the pigment melanin inside specialized compartments called melanosomes. Melan-A plays a behind-the-scenes role in building and maturing those compartments. Research has shown that Melan-A forms a complex with another melanosomal protein called Pmel17 (also known as gp100) and influences its expression, stability, and trafficking. Without Melan-A, Pmel17 cannot function properly, and melanosomes fail to mature normally. In that sense, Melan-A is essential for the pigmentation process, even though it is not directly making melanin.¹

Within the cell, Melan-A is found at its highest concentrations in the trans-Golgi network and on the outer membranes of early-stage melanosomes. As melanosomes mature, Melan-A levels decrease and the protein shifts to internal membrane structures. This pattern suggests Melan-A does most of its work during the early assembly phase of melanosomes rather than at later stages.²

The gene encoding Melan-A, called MLANA, is turned on by a master regulator of melanocyte development known as MITF. When researchers increased or decreased MITF activity in melanoma cells, MLANA expression followed in lockstep. MITF binds directly to specific sequences in the MLANA gene’s promoter region, confirming it as a direct transcriptional target.³ This tight link to MITF explains why Melan-A expression is so closely tied to melanocyte identity and why it tends to be lost when melanoma cells dedifferentiate.

Why Pathologists Use Melan-A to Diagnose Melanoma

Because Melan-A is produced abundantly by melanocytes and melanoma cells, it makes a useful flag for pathologists trying to determine whether a suspicious skin lesion is melanocytic in origin. In routine practice, a thin slice of tissue is stained with an antibody that binds Melan-A. If the cells light up, the pathologist gains confidence that they are looking at melanocytes or melanoma rather than some other cell type. This technique, called immunohistochemistry, is one of the standard tools in melanoma workup.

Melan-A does not work alone, though. Pathologists typically use it alongside other melanocytic markers such as S100, HMB-45, and SOX10. Each has strengths and weaknesses. In a comparison of these stains in benign melanocytic lesions, Melan-A and SOX10 each identified about 20% more melanocytes than HMB-45, with no meaningful difference between SOX10 and Melan-A themselves.⁴ In metastatic melanoma detected through lymph node samples, however, the picture shifts: S100 and SOX10 achieved perfect sensitivity, while Melan-A and HMB-45 fell short in some cases.⁵ SOX10 has also shown stronger staining intensity and a higher percentage of tumor cells stained in sentinel lymph nodes compared with Melan-A.⁶

So why not just use SOX10 every time? Partly because Melan-A has its own diagnostic niches. For example, a dual stain pairing Melan-A with 5-hydroxymethylcytosine (5-hmC) has proven effective at distinguishing benign nevus cells found in lymph nodes from actual metastatic melanoma. In one study, almost all metastatic melanomas lost nuclear 5-hmC expression while remaining strongly Melan-A positive, whereas benign nodal nevi retained both markers. That two-marker approach offers a practical first-line test for evaluating sentinel lymph node biopsies.⁷

Where Melan-A Staining Falls Short

Melan-A is not foolproof. Its biggest blind spot is desmoplastic melanoma, a rare subtype in which the tumor cells look more like scar tissue fibroblasts than typical melanoma. In a study of desmoplastic melanomas, only 3 out of 43 cases showed Melan-A positivity in the spindle-cell component of the tumor.⁸ Gene expression profiling has confirmed that desmoplastic melanomas downregulate multiple melanocyte differentiation genes, explaining their resistance to standard melanocytic stains.⁹ For these tumors, SOX10 and S100 tend to be more reliable identifiers.

Melan-A can also cause confusion outside melanoma entirely. Certain tumors called PEComas (perivascular epithelioid cell neoplasms), which arise in organs like the kidney, can stain positive for Melan-A along with HMB-45 and smooth muscle markers.¹⁰ Melan-A was originally discovered in melanoma cells and steroidogenic cells, meaning adrenal gland tumors and certain ovarian or testicular tumors can also express it.¹¹ Pathologists know to interpret Melan-A positivity in context. A Melan-A-positive mass in the skin strongly suggests melanocytic origin; the same result in the adrenal gland or kidney does not.

Melan-A as a Prognostic Marker

Beyond identifying melanoma, Melan-A expression can carry prognostic weight. An early study found that patients whose primary cutaneous melanoma lacked Melan-A expression had shorter disease-free intervals and worse overall survival, especially when the tumor was thicker than 1 mm.¹² More recent computational analyses of large melanoma datasets have reinforced this, showing that MLANA expression is linked to Breslow depth (the standard measure of tumor thickness) and to patient outcomes.¹³

The relationship is somewhat counterintuitive. Melan-A is overexpressed in melanoma tissue compared with normal skin, and higher expression has been associated with poor prognosis. Yet losing Melan-A entirely also signals danger, because it may mean the tumor has dedifferentiated to the point of evading immune recognition. The picture that emerges is one of a bell curve: moderate Melan-A expression reflects a well-differentiated tumor that the immune system can still see, while extremes in either direction raise concerns.

Researchers have also explored Melan-A as part of a panel for detecting circulating tumor cells in blood samples. Using mRNA biomarkers including MART-1/Melan-A alongside other markers, investigators have developed assays to track melanoma progression and predict clinical outcomes without needing a tissue biopsy.¹⁴ This type of “liquid biopsy” approach remains more of a research tool than a routine clinical test, but it underscores how Melan-A’s strong and consistent expression in melanoma cells makes it a practical molecular handle.

How the Immune System Sees Melan-A

Melan-A earned its alternate name MART-1 because it was discovered through the immune cells that recognize it. In the mid-1990s, researchers isolated the gene by studying cytotoxic T cells (killer immune cells) from melanoma patients that could destroy tumor cells. These T cells turned out to be recognizing small fragments of the Melan-A protein displayed on the surface of melanoma cells.¹⁵ The specific fragment, a short stretch of amino acids from position 26 to 35 of the protein, became one of the most studied targets in cancer immunology.

What makes Melan-A unusual among tumor antigens is how commonly the immune system already responds to it. Many melanoma patients have naturally occurring T cells that recognize Melan-A fragments, even before any treatment. Researchers have also identified additional Melan-A fragments that activate helper T cells, not just killer T cells, broadening the immune response that Melan-A can provoke.¹⁶ Helper T cells coordinate and sustain the broader immune attack, so engaging both arms of the T cell response is considered more effective than activating killer cells alone.

Melan-A in Immunotherapy

Given how visible Melan-A is to the immune system, it was a natural candidate for melanoma vaccines and other immunotherapies. Several approaches have been tested in clinical trials over the past two decades.

In one early trial, patients with resected high-risk melanoma received a peptide vaccine based on the Melan-A fragment MART-1(27-35). Over half of the patients developed a measurable immune response to the peptide, and those who did had longer relapse-free survival.¹⁷ These were early-phase safety trials, not definitive proof of efficacy, but they established that you could boost the anti-Melan-A immune response in patients and that doing so correlated with better outcomes.

A more sophisticated approach used dendritic cells, the immune system’s professional antigen-presenting cells, loaded with Melan-A. In a trial of patients with metastatic melanoma, dendritic cells were engineered with an adenovirus carrying the MART-1 gene and then injected back into patients. More than half the evaluated patients showed Melan-A-specific killer T cell responses, and some also mounted helper T cell responses. The vaccine was safe, though the trial was too small to draw firm conclusions about tumor shrinkage.¹⁸

More recently, researchers have moved into engineered T cell therapy. In a phase I/IIa trial, patients’ own T cells were genetically modified to carry a receptor specifically recognizing Melan-A, then infused back. About one in five assessable patients achieved a partial response, and the engineered cells persisted in proportion to the dose given.¹⁹ The response rates were modest, which reflects a broader challenge: melanoma is good at evolving ways to hide from the immune system, even when you send highly targeted immune cells after it.

When Melanoma Escapes by Losing Melan-A

One of the most frustrating aspects of targeting Melan-A is that melanoma cells can simply stop producing it. In a documented case, a patient’s melanoma lost Melan-A expression over a six-year period alongside downregulation of a protein called TAP-1, which is needed to load antigen fragments onto the cell surface for immune recognition. The result was a tumor that had become invisible to the very T cells trained to attack it.²⁰

This antigen-loss escape is a known problem for any immunotherapy that relies on a single target. If you train the immune system to recognize only Melan-A, you create strong selective pressure for tumor cells that have stopped expressing it. Those cells survive and expand, giving rise to a recurrent tumor that is resistant to the original therapy. This is one reason modern immunotherapy strategies often aim at multiple targets simultaneously or use broader-acting approaches like checkpoint inhibitors, which unleash the immune system more generally rather than directing it at one specific protein.

The Vitiligo Connection

Because Melan-A is a normal melanocyte protein, immune responses against it do not distinguish between melanoma cells and healthy melanocytes. This creates an ironic situation: effective anti-Melan-A immunity can cause vitiligo, the patchy loss of skin pigment that results from melanocyte destruction. In vitiligo patients who have never had melanoma, researchers have found high frequencies of circulating T cells that specifically recognize Melan-A and other melanocyte antigens. These cells showed the ability to kill melanocytes in laboratory tests and expressed markers associated with homing to the skin.²¹

In melanoma immunotherapy trials, vitiligo-like depigmentation has been observed as a side effect, sometimes accompanied by eye inflammation (uveitis), since melanocytes also live in the eye.²² Paradoxically, the development of vitiligo in melanoma patients receiving immunotherapy is often interpreted as a good sign, suggesting the immune response is vigorous enough to attack melanocyte-lineage cells throughout the body. Some studies have associated treatment-related vitiligo with better melanoma outcomes, though disentangling cause from correlation is tricky.

Melan-A Beyond Mammals

Melan-A’s involvement in pigmentation is not limited to humans. The MLANA gene shows up across vertebrates as part of the conserved machinery for melanosome assembly. In zebra finches, MLANA has been identified among the genes underlying sex-based differences in feather color. Males display bright red cheek patches, and MLANA expression differs between the sexes in cheek tissue in a way that suggests it contributes to the region-specific color pattern. Specifically, MLANA was reduced in female gray cheeks but not in other body regions, pointing to localized regulation of this pigmentation gene.²³

In reptiles, the broader melanosome-biogenesis pathway that Melan-A supports has been studied in the context of color morphs. While the most commonly implicated genes in reptile pigmentation changes are tyrosinase, SLC24A5, and OCA2, the melanosome maturation process they participate in is the same pathway Melan-A regulates.²⁴ This evolutionary conservation underscores that Melan-A is not a quirk of mammalian biology but part of an ancient toolkit for building pigmented cells, a toolkit that melanoma hijacks and that medicine has learned to exploit.